journal article·2024-05-06

Suit the Remedy to the Case: An Activatable DNA Damage Initiator for Postsurgical Therapy of Glioblastoma with TP53 Mutations

Yunfen Hua, Pingping Cao, Wenhong Wang, Haijiao Chen, Ziyi Hu, Suisui Yang, Yugang Ge, Heng Gao, Fan Lin, Hongshuai Wu

ACS Materials Letters· Volume 6· Issue 5
Publisher page

Abstract

Glioblastoma (GBM) with TP53 mutations is a typical subtype of intracranial tumors that rapidly recurs. Herein, we demonstrated that PD0166285 (PD), a dual-targeted inhibitor of WEE1 and PKMYT1, specifically activated DNA damage of TP53-mutant GBM cells for inducing a robust apoptotic effect. Suiting the remedy to the case, the injectable double-network hydrogels (DNHs) encapsulating PD were constructed on the basis of acid-sensitive Fe 3+ /tannic acid (TA) metal-phenolic networks (MPNs). Particularly, the incorporation of MPNs not only endowed PD-loaded hydrogels (PDNHs) with on-demand drug delivery but also controllably generated reactive oxygen species (ROS). Furthermore, ROS could amplify DNA damage stress, which demonstrated the potential of PDNHs as an activatable initiator to in situ trigger high-level DNA damage of TP53-mutant GBM cells. Thus, PDNHs remarkably restricted the postsurgical relapse of orthotopic GBM carrying TP53 mutations and improved the survival time of mice. This study presents a valuable strategy for suiting the remedy to postsurgical TP53-mutant GBM.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery · Glioma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P. R. China

Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, P. R. China

Wuxi Key Laboratory of Biomaterials for Clinical Application, Key Laboratory for Multidisciplinary Intersection of Radiotherapy and Immunology for Gastrointestinal Tumor, Department of Central Laboratory, Jiangyin Clinical College of Xuzhou Medical University, Wuxi 214400, P. R. China

Department of General Surgery, Jiangyin Clinical College of Xuzhou Medical University, Wuxi 214400, P. R. China

Department of Neurosurgery, Jiangyin Clinical College of Xuzhou Medical University, Wuxi 214400, P. R. China

Funding

Wuxi Health and Family Planning Commission · Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Affiliated Hospital Development Foundation of Xuzhou Medical University

References (45)

Show source-provided references
1. 10.1038/s41419-022-05304-810.1038/s41419-022-05304-8 ↗
2. 10.1016/j.cell.2023.12.01310.1016/j.cell.2023.12.013 ↗
3. 10.1016/j.biomaterials.2021.12091910.1016/j.biomaterials.2021.120919 ↗
4. 10.1016/j.jconrel.2022.03.05010.1016/j.jconrel.2022.03.050 ↗
5. 10.1002/adma.20210660610.1002/adma.202106606 ↗
6. 10.1021/acsnano.2c1021910.1021/acsnano.2c10219 ↗
7. Van Meir E. G. · Cancer Res. · 1994 · 54 · 649
8. 10.1038/s41573-022-00571-810.1038/s41573-022-00571-8 ↗
9. 10.18632/oncotarget.1119710.18632/oncotarget.11197 ↗
10. 10.1126/science.aax364910.1126/science.aax3649 ↗
11. 10.1016/j.ccell.2021.01.00310.1016/j.ccell.2021.01.003 ↗
12. 10.1038/nrclinonc.2017.15110.1038/nrclinonc.2017.151 ↗
13. 10.1186/s13046-018-0705-710.1186/s13046-018-0705-7 ↗
14. 10.1158/1535-7163.MCT-09-046310.1158/1535-7163.MCT-09-0463 ↗
15. 10.1038/s41580-021-00404-310.1038/s41580-021-00404-3 ↗
16. 10.1111/cpr.1274110.1111/cpr.12741 ↗
17. 10.1080/15384101.2021.192280610.1080/15384101.2021.1922806 ↗
18. 10.1038/s41586-022-04638-910.1038/s41586-022-04638-9 ↗
19. 10.1016/j.tips.2016.06.00610.1016/j.tips.2016.06.006 ↗
20. 10.1186/s13045-020-00959-210.1186/s13045-020-00959-2 ↗
21. 10.1038/nrc.2016.13810.1038/nrc.2016.138 ↗
22. 10.3390/molecules2212204510.3390/molecules22122045 ↗
23. 10.3389/fonc.2022.106198810.3389/fonc.2022.1061988 ↗
24. 10.1038/s41586-019-1607-310.1038/s41586-019-1607-3 ↗
25. 10.1016/j.celrep.2020.10790110.1016/j.celrep.2020.107901 ↗
26. Wang Y. · Cancer Res. · 2001 · 61 · 8211
27. 10.1038/s41578-021-00394-w10.1038/s41578-021-00394-w ↗
28. 10.1016/j.jconrel.2023.11.03710.1016/j.jconrel.2023.11.037 ↗
29. 10.1126/scitranslmed.abc780410.1126/scitranslmed.abc7804 ↗
30. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
31. 10.1021/acsnano.2c1009410.1021/acsnano.2c10094 ↗
32. 10.1021/acsami.2c0514710.1021/acsami.2c05147 ↗
33. 10.1002/adma.20210436210.1002/adma.202104362 ↗
34. 10.1038/s41565-020-00843-710.1038/s41565-020-00843-7 ↗
35. 10.1002/adfm.20220503810.1002/adfm.202205038 ↗
36. 10.1002/advs.20230521710.1002/advs.202305217 ↗
37. 10.1016/j.biomaterials.2019.04.02710.1016/j.biomaterials.2019.04.027 ↗
38. 10.1016/j.ccell.2015.09.01510.1016/j.ccell.2015.09.015 ↗
39. 10.1021/acs.nanolett.9b0211210.1021/acs.nanolett.9b02112 ↗
40. 10.1038/s41467-021-22572-810.1038/s41467-021-22572-8 ↗
41. 10.1021/jacs.1c0975310.1021/jacs.1c09753 ↗
42. 10.1021/acs.nanolett.8b0317810.1021/acs.nanolett.8b03178 ↗
43. 10.1002/smll.20210247010.1002/smll.202102470 ↗
44. 10.18632/oncotarget.1684710.18632/oncotarget.16847 ↗
45. 10.1038/s41419-020-2381-810.1038/s41419-020-2381-8 ↗